An update on the IMProved reduction of outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) design.

[1]  Michael Miller,et al.  Extended-release niacin or ezetimibe and carotid intima-media thickness. , 2009, The New England journal of medicine.

[2]  J. Kastelein,et al.  Statin therapy with ezetimibe or niacin in high-risk patients. , 2009, The New England journal of medicine.

[3]  M. Robson,et al.  Effects of high-dose modified-release nicotinic acid on atherosclerosis and vascular function: a randomized, placebo-controlled, magnetic resonance imaging study. , 2009, Journal of the American College of Cardiology.

[4]  Gert Mayer,et al.  Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. , 2009, The New England journal of medicine.

[5]  J. Fleg,et al.  Effect of statins alone versus statins plus ezetimibe on carotid atherosclerosis in type 2 diabetes: the SANDS (Stop Atherosclerosis in Native Diabetics Study) trial. , 2008, Journal of the American College of Cardiology.

[6]  R. Califf,et al.  Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. , 2008, American heart journal.

[7]  M. Landray,et al.  Analyses of cancer data from three ezetimibe trials. , 2008, The New England journal of medicine.

[8]  Thomas R Fleming,et al.  Identifying and addressing safety signals in clinical trials. , 2008, The New England journal of medicine.

[9]  J. Chambers,et al.  Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. , 2008, The New England journal of medicine.

[10]  Ralph B D'Agostino,et al.  Ezetimibe and cancer--an uncertain association. , 2008, The New England journal of medicine.

[11]  R. Giugliano,et al.  Baseline low-density lipoprotein cholesterol is an important predictor of the benefit of intensive lipid-lowering therapy: a PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) analysis. , 2008, Journal of the American College of Cardiology.

[12]  Allen J. Taylor,et al.  Preliminary Observations From Preliminary Trial Results: Have We Finally Had Enough? , 2008, Circulation. Cardiovascular quality and outcomes.

[13]  A. Zwinderman,et al.  Simvastatin with or without ezetimibe in familial hypercholesterolemia. , 2008, The New England journal of medicine.

[14]  S. Grundy.  Cardiovascular and metabolic risk factors: how can we improve outcomes in the high-risk patient? , 2007, The American journal of medicine.

[15]  Christopher P Cannon,et al.  Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. , 2006, Journal of the American College of Cardiology.

[16]  W. März,et al.  Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. , 2005, The New England journal of medicine.

[17]  N. Abate,et al.  Erratum: Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: The Vytorin Versus Atorvastatin (VYVA) Study (American Heart Journal (2005) 149 (464-473)) , 2005 .

[18]  N. Abate,et al.  Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: the Vytorin Versus Atorvastatin (VYVA) study. , 2005, American heart journal.

[19]  Neil J Stone,et al.  Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines , 2004, Circulation.

[20]  C. Baigent,et al.  Study of Heart and Renal Protection (SHARP). , 2003, Kidney international. Supplement.

[21]  R. Califf,et al.  Prognostic value of the admission electrocardiogram in acute coronary syndromes. , 1999, JAMA.

[22]  P. O'Brien,et al.  A multiple testing procedure for clinical trials. , 1979, Biometrics.

[23]  J. Mckenney,et al.  Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). , 2001, JAMA.